Verve Therapeutics VERV Stock
Verve Therapeutics Price Chart
Verve Therapeutics VERV Financial and Trading Overview
| Verve Therapeutics stock price | 3.85 USD |
| Previous Close | 17.1 USD |
| Open | 17.51 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1800 |
| Day's Range | 16.96 - 19.97 USD |
| 52 Week Range | 11.59 - 43 USD |
| Volume | 1.95M USD |
| Avg. Volume | 689.96K USD |
| Market Cap | 1.23B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.35 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.6 USD |
VERV Valuation Measures
| Enterprise Value | 630.44M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.1398964 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 367.3247 |
| Price/Book (mrq) | 2.4089363 |
| Enterprise Value/Revenue | 188.471 |
| Enterprise Value/EBITDA | -3.343 |
Trading Information
Verve Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 56.83% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 43 USD |
| 52 Week Low | 11.59 USD |
| 50-Day Moving Average | 16.3 USD |
| 200-Day Moving Average | 22.87 USD |
VERV Share Statistics
| Avg. Volume (3 month) | 689.96K USD |
| Avg. Daily Volume (10-Days) | 682.26K USD |
| Shares Outstanding | 61.93M |
| Float | 45M |
| Short Ratio | 21.1 |
| % Held by Insiders | 9.89% |
| % Held by Institutions | 105.09% |
| Shares Short | 12.36M |
| Short % of Float | 28.69% |
| Short % of Shares Outstanding | 19.96% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -5740.53% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.40% |
| Return on Equity (ttm) | -42.62% |
Income Statement
| Revenue (ttm) | 3.35M USD |
| Revenue Per Share (ttm) | 0.06 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -128154000 USD |
| EBITDA | -188604000 USD |
| Net Income Avi to Common (ttm) | -179196000 USD |
| Diluted EPS (ttm) | -3.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 508.69M USD |
| Total Cash Per Share (mrq) | 8.21 USD |
| Total Debt (mrq) | 80.11M USD |
| Total Debt/Equity (mrq) | 15.72 USD |
| Current Ratio (mrq) | 15.432 |
| Book Value Per Share (mrq) | 8.236 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -137920992 USD |
| Levered Free Cash Flow (ttm) | -98569128 USD |
Profile of Verve Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 201 Brookline Avenue |
| ZIP | 02215 |
| Phone | 617 603 0070 |
| Website | https://www.vervetx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 204 |
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Q&A For Verve Therapeutics Stock
What is a current VERV stock price?
Verve Therapeutics VERV stock price today per share is 3.85 USD.
How to purchase Verve Therapeutics stock?
You can buy VERV shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Verve Therapeutics?
The stock symbol or ticker of Verve Therapeutics is VERV.
Which industry does the Verve Therapeutics company belong to?
The Verve Therapeutics industry is Biotechnology.
How many shares does Verve Therapeutics have in circulation?
The max supply of Verve Therapeutics shares is 88.8M.
What is Verve Therapeutics Price to Earnings Ratio (PE Ratio)?
Verve Therapeutics PE Ratio is now.
What was Verve Therapeutics earnings per share over the trailing 12 months (TTM)?
Verve Therapeutics EPS is -2.35 USD over the trailing 12 months.
Which sector does the Verve Therapeutics company belong to?
The Verve Therapeutics sector is Healthcare.
Verve Therapeutics VERV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| Nasdaq US 700 Small Cap Value N NQUS700SCVN | 2110.21 USD — |
-7.44
|
— — | 2109.85 USD — | 2196.34 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2030.58 USD — |
-6.66
|
— — | 2030.36 USD — | 2092.28 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| Nasdaq US 700 Small Cap Value I NQUS700SCV | 1875.5 USD — |
-7.44
|
— — | 1875.17 USD — | 1952.05 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8098.63 USD — |
-5.98
|
— — | 8089.65 USD — | 8265.47 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}